Kerstin Allen

979 total citations
18 papers, 754 citations indexed

About

Kerstin Allen is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Kerstin Allen has authored 18 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 8 papers in Immunology. Recurrent topics in Kerstin Allen's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Kerstin Allen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Kerstin Allen collaborates with scholars based in United States, United Kingdom and Belgium. Kerstin Allen's co-authors include Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz, Ian W. Flinn, Brad S. Kahl, Pierluigi Porcu, Mark Douglas, Yasuhiro Oki, Manish R. Patel and Howard M. Stern and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Postgraduate Medical Journal.

In The Last Decade

Kerstin Allen

18 papers receiving 748 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerstin Allen United States 13 472 467 261 248 198 18 754
Julia Schaefer-Cutillo United States 5 419 0.9× 444 1.0× 148 0.6× 216 0.9× 182 0.9× 6 664
Ka Lung Wu Belgium 14 232 0.5× 210 0.4× 287 1.1× 76 0.3× 361 1.8× 39 708
Thomas M. Jahn United States 11 437 0.9× 636 1.4× 236 0.9× 219 0.9× 96 0.5× 22 743
C. von Schilling Germany 11 185 0.4× 91 0.2× 98 0.4× 134 0.5× 178 0.9× 22 498
Chengfeng Bi China 12 325 0.7× 88 0.2× 162 0.6× 97 0.4× 256 1.3× 29 536
Evgenii A. Osmanov Russia 6 352 0.7× 207 0.4× 110 0.4× 50 0.2× 316 1.6× 22 493
Dipti Patel‐Donnelly United States 13 216 0.5× 133 0.3× 130 0.5× 49 0.2× 197 1.0× 27 433
Jiaqin Yan China 13 338 0.7× 60 0.1× 118 0.5× 197 0.8× 310 1.6× 39 534
Claudia Corrado Argentina 14 336 0.7× 115 0.2× 207 0.8× 35 0.1× 265 1.3× 28 661
Anita Szőke United States 10 442 0.9× 1.0k 2.2× 358 1.4× 191 0.8× 128 0.6× 25 1.1k

Countries citing papers authored by Kerstin Allen

Since Specialization
Citations

This map shows the geographic impact of Kerstin Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerstin Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerstin Allen more than expected).

Fields of papers citing papers by Kerstin Allen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerstin Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerstin Allen. The network helps show where Kerstin Allen may publish in the future.

Co-authorship network of co-authors of Kerstin Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Kerstin Allen. A scholar is included among the top collaborators of Kerstin Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerstin Allen. Kerstin Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Flinn, Ian W., Manish R. Patel, Yasuhiro Oki, et al.. (2018). Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American Journal of Hematology. 93(11). 1311–1317. 26 indexed citations
2.
O’Brien, Susan, Manish R. Patel, Brad S. Kahl, et al.. (2018). Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal of Hematology. 93(11). 1318–1326. 48 indexed citations
3.
Flinn, Ian W., Susan O’Brien, Brad S. Kahl, et al.. (2017). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 131(8). 877–887. 183 indexed citations
4.
Horwitz, Steven M., Raphael Koch, Pierluigi Porcu, et al.. (2017). Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 131(8). 888–898. 204 indexed citations
5.
Casulo, Carla, Eric D. Jacobsen, Koen Van Eygen, et al.. (2016). Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.. Journal of Clinical Oncology. 34(15_suppl). e19052–e19052. 5 indexed citations
6.
Douglas, Mark, Kerstin Allen, Jennifer Sweeney, et al.. (2015). Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor.. Journal of Clinical Oncology. 33(15_suppl). 7072–7072. 2 indexed citations
7.
Patel, Manish R., Susan O’Brien, L. Kerrie, et al.. (2015). Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL.. Journal of Clinical Oncology. 33(15_suppl). 7074–7074. 9 indexed citations
8.
Schmalbach, Tess, Rainard Fuhr, Muna Albayaty, et al.. (2015). Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma. PA2122–PA2122. 9 indexed citations
9.
Porcu, Pierluigi, Ian W. Flinn, Brad S. Kahl, et al.. (2014). Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib. Blood. 124(21). 3335–3335. 26 indexed citations
10.
O’Brien, Susan, Manish R. Patel, Brad S. Kahl, et al.. (2014). Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 124(21). 3334–3334. 56 indexed citations
11.
Flinn, Ian W., Yasuhiro Oki, Manish R. Patel, et al.. (2014). a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL. Blood. 124(21). 802–802. 38 indexed citations
12.
Horwitz, Sarah McCue, Pierluigi Porcu, Ian W. Flinn, et al.. (2014). Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma. Blood. 124(21). 803–803. 35 indexed citations
13.
Horwitz, Steven M., Ian W. Flinn, Manish R. Patel, et al.. (2013). Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.. Journal of Clinical Oncology. 31(15_suppl). 8518–8518. 17 indexed citations
14.
15.
Flinn, Ian W., Manish R. Patel, Brad S. Kahl, et al.. (2013). Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia. Blood. 122(21). 677–677. 26 indexed citations
16.
Patel, Manish R., Brad S. Kahl, Steven M. Horwitz, et al.. (2013). Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL.. Journal of Clinical Oncology. 31(15_suppl). 7070–7070. 32 indexed citations
17.
Flinn, Ian W., Steven M. Horwitz, Manish R. Patel, et al.. (2012). Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies. Blood. 120(21). 3663–3663. 19 indexed citations
18.
Barclay, G R, Kerstin Allen, & C R Pennington. (1990). Tissue plasminogen activator in the treatment of superior vena caval thrombosis associated with parenteral nutrition. Postgraduate Medical Journal. 66(775). 398–400. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia Schaefer-Cutillo Breakdown of academic impact, for papers by Ka Lung Wu Breakdown of academic impact, for papers by Thomas M. Jahn Breakdown of academic impact, for papers by C. von Schilling Breakdown of academic impact, for papers by Chengfeng Bi Breakdown of academic impact, for papers by Evgenii A. Osmanov Breakdown of academic impact, for papers by Dipti Patel‐Donnelly Breakdown of academic impact, for papers by Jiaqin Yan Breakdown of academic impact, for papers by Claudia Corrado Breakdown of academic impact, for papers by Anita Szőke
Rankless by CCL
2026